Brief report: Leucine-rich α2-glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis

Arthritis and Rheumatology

Volumn 67, Issue 8, 2015, Pages 2056-2060

  Fujimoto, Minoru ^a   Serada, Satoshi ^a   Suzuki, Katsuya ^b   Nishikawa, Ayumi ^b   Ogata, Atsushi ^c   Nanki, Toshihiro ^d   Hattori, Kunihiro ^e   Kohsaka, Hitoshi ^d   Miyasaka, Nobuyuki ^d   Takeuchi, Tsutomu ^b   Naka, Tetsuji ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e Chugai Pharmaceutical   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; METHOTREXATE; STROMELYSIN; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; GLYCOPROTEIN; IL6R PROTEIN, HUMAN; LRG1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; BIOLOGICAL THERAPY; BONE DESTRUCTION; CARTILAGE DEGENERATION; CHRONOTHERAPY; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; CORTICOSTEROID THERAPY; DAS28; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; EXPERIMENTAL ARTHRITIS; FEMALE; GRANULOMATOUS INFLAMMATION; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; METABOLISM; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 84938117854     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39164     Document Type: Article

References (16)

1. Tanaka T, Ogata A, Kishimoto T., Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatology (Sunnyvale) 2013. http://omicsonline.org/targeting-of-interleukin-6-for-the-treatment-of-rheumatoid-arthritis-review-and-update-2161-1149.S4-002.php?aid=18750.
2. Gabay C, Kushner I., Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
3. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
4. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
5. Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, et al., iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis 2010; 69: 770-4.
6. Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, et al., Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 2012; 18: 2169-79.
7. 2-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun 2009; 382: 776-9.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
9. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al., American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
10. Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, et al., A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood. PLoS One 2014; 9: e86184.
11. Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M., Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull 2008; 31: 1159-63.
12. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al., Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28: 1203-7.
13. Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M., Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol 2008; 84: 262-70.
14. Sharif M, Salisbury C, Taylor DJ, Kirwan JR., Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 1998; 41: 1203-9.
15. Wang X, Abraham S, McKenzie JA, Jeffs N, Swire M, Tripathi VB, et al., LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature 2013; 499: 306-11.
16. Colebatch AN, Edwards CJ, Ostergaard M, van der Heijde D, Balint PV, D'Agostino MA, et al., EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013; 72: 804-14.